JAK1 and lung carcinoma: Previous studies have shown that EGFR mutation increased IL-6 expression and therefore activated STAT3 via IL-6/gp130/JAK1 signal pathway25, 44 and JAK1 was the critical JAK receptor kinase in IL-6/gp130/JAK/STAT3 signal pathway in lung cancer cells27.